Eli Lilly's new weight-loss drug wows Wall Street — ride the breakout higher

Verdict: a strong thesis, but no signal — wait for the stacked confirmation

The fundamentals behind the thesis are real: revenue of $23.0B in the June 2026 quarter, up 16.0% sequentially, operating cash flow of $10.7B, up 100.5%, and gross margin of 85.8% — but the trade is not on. The entry needs a close above the 5-day high of $1,150.69 (about 1.1% above the last close of $1,138.35) **and** RSI(14) above 60; RSI at 34.4 is the binding constraint. Against the idea, net margin fell 17.3% quarter over quarter to 30.9%, debt-to-equity jumped 11.9% to 1.41, and the ownership filing for the period ended June 30, 2026 shows net insider open-market selling of roughly $2.9M. The setup has never triggered across 1,234 daily bars in five years, and no robust parameter setup was established, so this is a watch-list idea, not an active signal. Wait for the stacked confirmation; check each daily close against $1,150.69 and RSI against 60.

Trade now: LLY breakout — armed, not triggered

Nothing to buy yet. LLY closed at $1,138.35, and the strategy needs a close above the 5-day high of $1,150.69 — about $12.34, or roughly 1.1% higher — plus daily RSI(14) above 60. Price is close on the first leg, and the stock already sits above the nearest resistance level at $1,134.31, but the momentum gate is the problem: RSI(14) is 34.4, more than 25 points below the required 60. That is not a one-day fix; it usually takes a sustained rally. The idea argues institutional money flows in for weeks after the obesity-drug trial beat, which is exactly the kind of move that could lift RSI — but today, that is a forecast, not a signal. If the entry triggers, the exits do the risk management for you: a close back below the 10-day moving average (currently $1,170.80, so it will have moved by entry), or a 5% trailing stop, whichever hits first, plus a hard take-profit at +10% and a Fibonacci extension target at the 127.2% level. Until entry, "wait" means precisely this: check each daily close against $1,150.69 and RSI against 60, and do nothing on intraday prints. One caution worth weighing before entry: the most recent ownership filing (period ending June 30, 2026) shows net open-market insider selling of roughly $2.88M across 23 holders. That does not block a momentum entry, but if the stock needs a breakout to justify the thesis, insiders trimming into strength is a mild counterweight. Note on validation: the historical check found zero triggers across 1,234 daily bars over five years — the stacked entry conditions simply have not co-occurred on a single bar. That makes this a watch-list setup, and no robust alternative parameter setup was established, so the published rules are the ones to follow.

Why the bull case still has support

The core of this idea — that a strong next-generation obesity readout confirms pipeline durability and should attract institutional flows over days and weeks — is a thesis about durable growth, and the reported fundamentals back up that framing. Revenue in the quarter ended June 30, 2026 came in at $23.0B, up 16.0% from the prior quarter's $19.8B, and the Q4 2025 snapshot showed year-over-year revenue growth of 42.5%, placing Lilly in roughly the top quarter (74th percentile) of 752 Health Care peers. That is the kind of top-line trajectory that keeps the obesity franchise story credible even as competitors arrive. Quality metrics support the idea that this growth is not being bought at the expense of profitability. Gross margin reached 85.8% in the June 2026 quarter, up 4.7% sequentially and the highest in the supplied series — a level in the 79th…

Scores

• Conviction score breakdown: 51
• Thesis support: 75
• Trade readiness: 35
• Risk quality: 55
• Trigger proximity: 20
• Fundamentals trend: 70

Watch items

• LLY — Daily close vs Donchian (5) upper
• LLY — RSI (14)
• LLY — Close vs first resistance
• LLY — Close vs SMA (10)
• LLY — Insider net open-market activity
• LLY — Quarterly net margin
• LLY — Dividend ex-date